USA David H. Crean, Ph.D., is a San Diego-based venture capitalist and strategic advisor with over 30 years of experience in life sciences and healthcare. Drawing on a deep personal connection to Alzheimer’s disease as well as decades of experience as a scientist and investor, Crean casts his eye over the…
Saudi Arabia Dr Adel AlMarshad, MD MPH serves as General Supervisor for the Health and Biotechnology Sectors at the Royal Commission for Riyadh City (RCRC) as well as Executive Director of Riyadh Megaprojects in Health, Biotechnology, and Medical Tourism. Dr. El Marshad discusses the RCRC’s pivotal role in transforming Riyadh into a global…
Germany Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. looks out over the choppy waters for life sciences venture capitalists in Europe over 2025. Three key initiatives stand to reshape the continent’s investment climate, but broader geopolitical winds – especially those now emanating from the White House – could…
Europe Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine and rare diseases and its implications for IP law. Personalised medicine, also referred to as precision medicine, is an…
France At the end of a turbulent and lengthy process, France’s 2025 health budget has finally been approved. This “imperfect” budget resulting from months of debate in a parliament with no absolute majority does not embrace the more radical cost-cutting measures originally proposed. It does raise funding for hospitals by EUR…
Saudi Arabia Dr. Helmut M. Schuehsler, CEO of TVM Capital Healthcare, shares insights into the firm’s investment strategy spanning the Middle East and Southeast Asia with a particular focus on Saudi Arabia’s rapidly evolving healthcare landscape. He discusses how TVM Capital Healthcare is driving transformation by scaling healthcare businesses, introducing innovative care…
Global Since Paul Hudson took the helm in 2019, Sanofi has been in transformation mode, shedding its consumer health assets to focus on high-growth areas like oncology, immunology, and vaccines. With bold investments in R&D and AI-driven innovation, the French pharma is positioning itself as a pure-play biopharma leader. In conversation…
Saudi Arabia Baraya Extended Care is reshaping Saudi Arabia’s healthcare system, addressing critical gaps in long-term care and rehabilitation with bold innovation and a scalable vision. Backed by TVM Capital Healthcare Partners, it integrates advanced technologies and strategic partnerships to redefine specialized care while aligning with Vision 2030. As CEO Jad Halaby…
Europe European pharma is at a turning point, with rising cost pressures, regulatory shifts, and supply chain vulnerabilities reshaping the industry. As the new president of Medicines for Europe, STADA’s Stephan Eder is now at the forefront of driving the change that Europe needs. In this new role as head of…
Mexico In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms of prevalence, a full two-thirds of the adult Mexican population are nowadays classified as overweight or obese. “This is a…
Mexico Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an economic outflow of over 240 million dollars per annum in the process. Indeed, most of the major biopharma multinationals now…
Saudi Arabia Three leading lights from biopharma, policy, and research come together in Riyadh to discuss the current treatment and prevention landscape for Alzheimer’s disease. As people live longer, the threat of age-related diseases deepens. Alzheimer’s, one of the cruellest such diseases, therefore represents an increasingly urgent public health challenge in…
See our Cookie Privacy Policy Here